Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM-120 low-dose LSD for adult ADHD
NL-OMON52408Phase 2Active, not recruiting
- Sponsor
- MindMed
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing Placebo with MM-120 (2 arms). Primary endpoint: Change from baseline in AISRS at 6 weeks. Started Jan 2022; status: active, not recruiting.
02
Drugs
lysergic acid diethylamide D-tartrate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NL-OMON52408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52408.